Products

LIPONORM

Liponorm 10 mg: Each tablet contains: Atorvastatin calcium trihydrate: 10.85 mg.
Liponorm 20 mg: Each tablet contains: Atorvastatin calcium trihydrate: 21.70 mg.
Liponorm 40 mg: Each tablet contains: Atorvastatin calcium trihydrate: 40 mg.

Liponorm (Atorvastatin) is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

View PDF



Full Product Information

Back

FEATURED

Articles

Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy

In this population-based cohort study of 29 047 patients, there was evidence that discontinuing therapy with statins was associated with a significantly increased risk of hospital admission for heart failure and any cardiovascular outcome, death from any cause, and emergency admission for any cause. Meaning The findings of this study suggest that discontinuing statins while maintaining other drug therapiesmay increase the long-term risk of fatal and nonfatal cardiovascular outcomes.

SEE MORE

Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis

This meta-analysis of retrospective observational studies showed that statin therapy was associated with an about 35% decrease in the adjusted risk of mortality in hospitalized COVID-19 patients.

SEE MORE

COVID-19: Direct and Indirect Mechanisms of Statins

Recent studies indicate that statin therapy is associated with decreased mortality in COVID-19, which may be caused by direct and indirect mechanisms. According to literature data, statins can limit SARS-CoV-2 cell entry and replication by inhibiting the main protease (Mpro) and RNA-dependent RNA polymerase (RdRp). The cytokine storm can be ameliorated by lowering serum IL-6 levels; this can be achieved by inhibiting Toll-like receptor 4 (TLR4) and modulating macrophage activity. Statins can also reduce the complications of COVID-19, such as thrombosis and pulmonary fibrosis, by reducing serum PAI-1 levels, attenuating TGF- and VEGF in lung tissue, and improving endothelial function.

SEE MORE

The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis

Patients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.

SEE MORE
Founded in 1967, Droguerie Phenicia is dedicated to improving the health of the Lebanese society and providing it access to affordable healthcare. Our company strives to help people live longer, healthier and trouble-free lives.

Media

NAVIGATION

© 2023 All right reserved.
The contents of this website are not intended to substitute for professional medical advice, diagnosis or treatment.
Although we take efforts to keep the medical information on our website updated.
Please consult your physician for personalized medical advice.